학술논문
Neisseria meningitidis Serogroup W, Burkina Faso, 2012.
Document Type
Article
Author
MacNeil, Jessica R.; Medah, Isaïe; Koussoubé, Daouda; Novak, Ryan T.; Cohn, Amanda C.; Diomandé, Fabien V.K.; Yelbeogo, Denis; Kambou, Jean Ludovic; Tarbangdo, Tiga F.; Ouédraogo-Traoré, Rasmata; Sangaré, Lassana; Hatcher, Cynthia; Vuong, Jeni; Mayer, Leonard W.; Djingarey, Mamoudou H.; Clark, Thomas A.; Messonnier, Nancy E.
Source
Subject
*MENINGOCOCCAL vaccines
*NEISSERIA meningitidis
*EPIDEMIOLOGICAL research
*VACCINE research
*VIRUS diseases
*
*
*
*
Language
ISSN
1080-6040
Abstract
In 2010, Burkina Faso became the first country to introduce meningococcal serogroup A conjugate vaccine (PsA-TT). During 2012, Burkina Faso reported increases in Neisseria meningitidis serogroup W, raising questions about whether these cases were a natural increase in disease or resulted from serogroup replacement after PsA-TT introduction. We analyzed national surveillance data to describe the epidemiology of serogroup W and genotyped 61 serogroup W isolates. In 2012, a total of 5,807 meningitis cases were reported through enhanced surveillance, of which 2,353 (41%) were laboratory confirmed. The predominant organism identified was N. meningitidis serogroup W (62%), and all serogroup W isolates characterized belonged to clonal complex 11. Although additional years of data are needed before we can understand the epidemiology of serogroup W after PsA-TT introduction, these data suggest that serogroup W will remain a major cause of sporadic disease and has epidemic potential, underscoring the need to maintain high-quality case-based meningitis surveillance after PsA-TT introduction. [ABSTRACT FROM AUTHOR]